CARDIZEM
What it isNon-dihydropyridine calcium channel blocker; rate control in atrial fibrillation, angina and hypertension.
Why this oneCompared with verapamil, it causes less constipation and myocardial depression while retaining AV-nodal rate control.
What limits itNegative inotrope: avoid in reduced EF. A moderate CYP3A4 inhibitor, which matters with statins and tacrolimus.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Chronic stable angina; angina due to coronary artery spasm | Adults | 30 mg QID (before meals and at bedtime) | 180–360 mg/day divided TID–QID | 360 mg/day (usual optimum range upper limit) |
Titration Increase gradually at 1–2 day intervals until optimum response.
Renal Undefined (no dosing data; titrate with particular caution).
Hepatic Undefined (no dosing data; titrate with particular caution).
Pregnancy Animal embryo/fetal lethality and skeletal abnormalities; use only if potential benefit justifies risk.
Lactation Undefined.
NO BOXED WARNINGS
Principal riskBradycardia and heart block; a moderate CYP3A4 inhibitor
Cost, est. cash$4–$80/month
Generic entry1992
Legacy pregnancy categoryC
Defining liabilityBradycardia, heart block and hypotension; overdose can cause refractory cardiogenic shock.

Open Diltiazem in the interactive console ↗

